Sarthak’s Q3 FY24 results impacted by low demand

Sarthak Metals has battled volatile input and metal prices driven by weak Chinese and Global economy in the last 2-3 quarters. Revenues were down 19% y-o-y in Q3 ‘24 to Rs 75 crore due to muted exports in the cored wire segment and uncharacteristic margin squeeze in the aluminium segment….

Read More

CL Educate builds on its growth momentum in Q1 FY24

CL Educate revenues were up about 30% in Q1 FY’24, with strong growth in both EdTech and MarTech business. The management has been saying it is focused on delivering strong growth henceforth, the Q1 results show it is walking the talk. Drilling down, EdTech and MarTech registered 33% and 23%…

Read More

Indrayani Biotech shows robust growth in FY23

Indrayani Biotech Limited (IBL) clocked a strong growth trajectory in FY23 with consolidated revenues of Rs 167 crore, as compared to revenue of Rs 62 crore in FY22. FY23 turned out to be a transformational year, with revenue growth of 171%. EBITDA margins also showed an upward trend. Indrayani reported…

Read More

CL Educate’s Q3 results reflect continued growth

Growth momentum continued in Q3 FY23 despite Q3 traditionally being the weakest quarter due to exams. EdTech and MarTech revenues were up 31% and 22% respectively on a y-o-y basis. CL has crossed FY22 revenue and EBITDA in 9m FY23. While much of this recovery is due to return to…

Read More

Chemcrux is planning a bigger future now

The first half of FY22 has seen some significant steps taken by the Chemcrux management, that signify a more aggressive intent towards the future growth of the company. Financial performance of FY22H1 has been good as well, with net profit increasing 16% over FY21H1, which was impacted by Covid.  The…

Read More

CL’s Career Launcher targeting 7x network expansion in 3 years

We have written earlier that Edtech and Martech player CL Educate is a stock in a positive upcycle. FY22 has already seen a chain of positive developments. CL’s newsletter for its Test Prep business for Nov’21 shows the rapid pace of developments at the company. Some key snippets: CL is…

Read More

CL Educate Q2: Recovery picks up speed

After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…

Read More

USD 3.3B of VC/PE investment in lifesciences firms in Sep’21

We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…

Read More

Sales Multiple Biryani or PE Biryani

The other day I was talking to a person who is an early-stage investor. He was looking to invest in a food business. He explained to me his criterion: he said his fund wanted to invest in a sales-multiple food business. This foxed me. I have heard of packaged food…

Read More

USD 6.5B of VC/PE investment in lifesciences firms in June’21

We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…

Read More